About the bill
About 37.2% of American adults use medications with depression and the risk of suicide as a potential side effect. Should the risks be more explicitly stated?
What the bill does
The Depression Side Effect Labeling Awareness Act [H.R. 6717] would require that “warnings and precautions in the drug’s label include an increased risk of suicide or depression” with such information being “presented prominently.”
The Commissioner of Food and Drugs, currently Scott Gottlieb, would be required to carry out the order through their agency within a year of passage.
The bill was introduced in the House on September 6 by Rep. Bobby Rush (D-IL1).
What supporters say
Supporters argue the bill would provide the public needed information, similar to the requirement of nutrition facts on food.
“There are ...
Sponsor and status
Sponsor. Representative for Illinois's 1st congressional district. Democrat.
Last Updated: Sep 6, 2018
Length: 2 pages
115th Congress (2017–2019)
This bill was introduced on September 6, 2018, in a previous session of Congress, but it did not receive a vote.
Sep 6, 2018
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
Sep 19, 2019
Reintroduced Bill — Introduced
This activity took place on a related bill, H.R. 4404 (116th).
H.R. 6717 (115th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number H.R. 6717. This is the one from the 115th Congress.
This bill was introduced in the 115th Congress, which met from Jan 3, 2017 to Jan 3, 2019. Legislation not passed by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2021). H.R. 6717 — 115th Congress: Depression Side Effect Labeling Awareness Act of 2018. Retrieved from https://www.govtrack.us/congress/bills/115/hr6717
“H.R. 6717 — 115th Congress: Depression Side Effect Labeling Awareness Act of 2018.” www.GovTrack.us. 2018. January 26, 2021 <https://www.govtrack.us/congress/bills/115/hr6717>
Depression Side Effect Labeling Awareness Act of 2018, H.R. 6717, 115th Cong..
|title=H.R. 6717 (115th)
|accessdate=January 26, 2021
|author=115th Congress (2018)
|date=September 6, 2018
|quote=Depression Side Effect Labeling Awareness Act of 2018
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.